<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer Res Treat</journal-id><journal-id journal-id-type="iso-abbrev">Breast Cancer Res Treat</journal-id><journal-title-group><journal-title>Breast Cancer Research and Treatment</journal-title></journal-title-group><issn pub-type="ppub">0167-6806</issn><issn pub-type="epub">1573-7217</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39302578</article-id><article-id pub-id-type="pmc">PMC11785639</article-id>
<article-id pub-id-type="publisher-id">7474</article-id><article-id pub-id-type="doi">10.1007/s10549-024-07474-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Genetic variants and social benefit receipt in premenopausal women with breast cancer treated with docetaxel: a Danish population-based cohort study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7733-8750</contrib-id><name><surname>Schmidt</surname><given-names>Julie A.</given-names></name><address><email>js@clin.au.dk</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4378-8531</contrib-id><name><surname>Hjorth</surname><given-names>Cathrine F.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8577-048X</contrib-id><name><surname>Farkas</surname><given-names>D&#x000f3;ra K.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0591-7187</contrib-id><name><surname>Damkier</surname><given-names>Per</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3262-3299</contrib-id><name><surname>Feddersen</surname><given-names>S&#x000f8;ren</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2158-3885</contrib-id><name><surname>Hamilton-Dutoit</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8761-714X</contrib-id><name><surname>Ejlertsen</surname><given-names>Bent</given-names></name><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5240-5195</contrib-id><name><surname>Lash</surname><given-names>Timothy L.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0440-8727</contrib-id><name><surname>Ahern</surname><given-names>Thomas P.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9738-2284</contrib-id><name><surname>Cronin-Fenton</surname><given-names>Deirdre</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01aj84f44</institution-id><institution-id institution-id-type="GRID">grid.7048.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 1956 2722</institution-id><institution>Department of Clinical Epidemiology, Department of Clinical Medicine, </institution><institution>Aarhus University and Aarhus University Hospital, </institution></institution-wrap>Olof Palmes All&#x000e9; 43-45, 8200 Aarhus N, Denmark </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00ey0ed83</institution-id><institution-id institution-id-type="GRID">grid.7143.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0512 5013</institution-id><institution>Department of Clinical Pharmacology, </institution><institution>Odense University Hospital, </institution></institution-wrap>Odense, Denmark </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03yrrjy16</institution-id><institution-id institution-id-type="GRID">grid.10825.3e</institution-id><institution-id institution-id-type="ISNI">0000 0001 0728 0170</institution-id><institution>Department of Clinical Research, </institution><institution>University of Southern Denmark, </institution></institution-wrap>Odense, Denmark </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00ey0ed83</institution-id><institution-id institution-id-type="GRID">grid.7143.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0512 5013</institution-id><institution>Department of Clinical Biochemistry, </institution><institution>Odense University Hospital, </institution></institution-wrap>Odense, Denmark </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/040r8fr65</institution-id><institution-id institution-id-type="GRID">grid.154185.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0512 597X</institution-id><institution>Department of Clinical Medicine and Department of Pathology, </institution><institution>Aarhus University Hospital, </institution></institution-wrap>Aarhus, Denmark </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/035b05819</institution-id><institution-id institution-id-type="GRID">grid.5254.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0674 042X</institution-id><institution>Danish Breast Cancer Group, Department of Oncology, Rigshospitalet, </institution><institution>University of Copenhagen, </institution></institution-wrap>Copenhagen, Denmark </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/035b05819</institution-id><institution-id institution-id-type="GRID">grid.5254.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0674 042X</institution-id><institution>Department of Clinical Medicine, Faculty of Health and Medical Sciences, </institution><institution>University of Copenhagen, </institution></institution-wrap>Copenhagen, Denmark </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03czfpz43</institution-id><institution-id institution-id-type="GRID">grid.189967.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7398</institution-id><institution>Department of Epidemiology, Rollins School of Public Health, </institution><institution>Emory University, </institution></institution-wrap>Atlanta, GA USA </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0155zta11</institution-id><institution-id institution-id-type="GRID">grid.59062.38</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7689</institution-id><institution>Department of Surgery, The Robert Larner, M.D. College of Medicine, </institution><institution>The University of Vermont, </institution></institution-wrap>Burlington, VT USA </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>209</volume><issue>1</issue><fpage>73</fpage><lpage>84</lpage><history><date date-type="received"><day>9</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>25</day><month>8</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">Breast cancer patients&#x02019; need for social benefits may increase following taxane-based chemotherapy, due to long-lasting side effects. Specific single nucleotide polymorphisms (SNPs) may mediate such side effects. We investigated the association between SNPs related to taxane metabolism, transport, toxicity, or DNA and neural repair, and receipt of social benefits.</p></sec><sec><title>Methods</title><p id="Par2">From the Danish Breast Cancer Group, we identified premenopausal women diagnosed with stage I&#x02013;III breast cancer during 2007&#x02013;2011 and treated with docetaxel-based chemotherapy. We genotyped 21 SNPs from archived breast tumors using TaqMan assays. We ascertained social benefit payments from 1 year before to 5 years after diagnosis, using nationwide, administrative registry data. For each week, we categorized women as receiving health-related benefits (including sick leave and disability pension), labor market-related benefits (including unemployment benefits), or as being self-supporting. We computed rate ratios (RRs) of social benefit receipt for variant carriers (heterozygotes plus homozygotes) vs. non-carriers, using negative binominal regression with robust variance estimation.</p></sec><sec><title>Results</title><p id="Par3">Among 2430 women, 12% received health-related benefits before diagnosis, 80% at diagnosis, and&#x02009;~&#x02009;24% 2 to 5 years after diagnosis. Labor market-related benefits were uncommon (3&#x02013;6%). All RRs were near-null and/or imprecise.</p></sec><sec><title>Conclusion</title><p id="Par4">We found no clinically meaningful impact of the selected SNPs on social benefit receipt among premenopausal breast cancer survivors treated with docetaxel.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s10549-024-07474-9.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Breast cancer</kwd><kwd>Single-nucleotide polymorphisms</kwd><kwd>Social benefits</kwd><kwd>Survivorship</kwd><kwd>Taxane</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008363</institution-id><institution>Kr&#x000e6;ftens Bek&#x000e6;mpelse</institution></institution-wrap></funding-source><award-id>R359-A21368</award-id><award-id>R327-A19070</award-id><principal-award-recipient><name><surname>Schmidt</surname><given-names>Julie A.</given-names></name><name><surname>Cronin-Fenton</surname><given-names>Deirdre</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005940</institution-id><institution>Dansk Kr&#x000e6;ftforsknings Fond</institution></institution-wrap></funding-source><award-id>FID1839672</award-id><principal-award-recipient><name><surname>Hjorth</surname><given-names>Cathrine F.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>US National Cancer Institute</institution></funding-source><award-id>R01CA166825</award-id><principal-award-recipient><name><surname>Lash</surname><given-names>Timothy L.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100009708</institution-id><institution>Novo Nordisk Fonden</institution></institution-wrap></funding-source><award-id>NNF19OC0058710</award-id><principal-award-recipient><name><surname>Cronin-Fenton</surname><given-names>Deirdre</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003554</institution-id><institution>Lundbeck Foundation</institution></institution-wrap></funding-source><award-id>R167&#x02013;2013&#x02013;15861</award-id><principal-award-recipient><name><surname>Cronin-Fenton</surname><given-names>Deirdre</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Aarhus Universitet</institution></funding-source></award-group><open-access><p>Open access funding provided by Aarhus Universitet</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par20">Women aged less than 55 years represent over 40% of newly diagnosed breast cancer cases [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. High incidence rates and improved survival have increased the number of breast cancer survivors, many of whom are working at the time of diagnosis.</p><p id="Par21">Taxane-based adjuvant chemotherapy (docetaxel or paclitaxel) is a cornerstone of breast cancer treatment, yet may be associated with potentially long-lasting, severe, and even debilitating side effects including peripheral neuropathy and fatigue [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. These side effects may compromise recovery after breast cancer. Women treated with chemotherapy are more likely to experience sick leave [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>] and impaired return-to-work [<xref ref-type="bibr" rid="CR8">8</xref>] compared with those not receiving chemotherapy. Loss of work among cancer survivors has a negative impact on quality of life [<xref ref-type="bibr" rid="CR8">8</xref>] and may have adverse consequences for the economy of both the individual patient and society [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par22">The severity of peripheral neuropathy after taxane-based chemotherapy may partly depend on single nucleotide polymorphisms (SNPs) in genes encoding enzymes involved in taxane metabolism, transport, toxicity, and in DNA or neural repair [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. In turn, these genetic variants may help identify patients in greater need for sick leave compensation, disability pension, or other benefits. In our recent study conducted within the Predictors of Breast Cancer Recurrence (ProBe CaRe) cohort, we investigated the association between selected SNPs and return-to-work after a breast cancer diagnosis [<xref ref-type="bibr" rid="CR15">15</xref>]. The study showed that most women returned to work within 1 year of diagnosis. Our findings also suggested that women homozygous for the <italic>CYP3A5</italic> rs776746 allele took longer to return-to-work compared with non-carriers, although the estimate of association was imprecise. The association between SNPs and receipt of specific types of social benefits has not been examined.</p><p id="Par23">We identified 21 SNPs related to taxane metabolism, transport, toxicity, and DNA and neural repair. We investigated their association with receipt of social benefits, from 1 year before diagnosis to 5 years after diagnosis, among premenopausal women diagnosed with breast cancer.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Setting and design</title><p id="Par24">We conducted a population-based cohort study in Denmark, linking individual-level data from nationwide registries, clinical databases, and biobanks. Data linkage was accomplished with the civil personal registration number, a unique identifier assigned to all residents of Denmark at birth or immigration [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par25">Denmark has a tax-supported healthcare system, ensuring free-of-charge&#x000a0;care provided to all residents by general practitioners in the community and by hospitals [<xref ref-type="bibr" rid="CR16">16</xref>]. Patients with invasive breast cancer are registered in the Danish Breast Cancer Group (DBCG) clinical database, which compiles clinical and demographic characteristics at the time of breast cancer diagnosis including tumor stage, grade, human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER) status, guideline-based recommended treatments (including chemotherapy), received treatments, age, and menopausal status [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. In Denmark, all diagnostic formalin-fixed paraffin-embedded (FFPE) tissue biopsies are routinely archived in perpetuity at local pathology departments, and logged in the Danish National Pathology Registry [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par26">In addition to tax-supported healthcare, the Danish government offers subsistence and unemployment payments, student grants, and a range of other social and health-related benefits to residents in need. Such transfer payments have been registered on a weekly basis in the Danish Register for Evaluation of Marginalization (DREAM) since 1991 [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par27">Information on comorbidities, cohabitation, and level of education were obtained from the Danish National Patient Registry [<xref ref-type="bibr" rid="CR22">22</xref>], Statistics Denmark [<xref ref-type="bibr" rid="CR23">23</xref>], and the Danish Population&#x02019;s Education Registry [<xref ref-type="bibr" rid="CR24">24</xref>], respectively.</p></sec><sec id="Sec4"><title>Study cohort</title><p id="Par28">The ProBe CaRe cohort includes 5959 premenopausal women diagnosed with stage I&#x02013;III breast cancer across Denmark from 2002 to 2011 and registered in the DBCG [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Only women with ER-positive tumors who received tamoxifen (ER&#x02009;+/TAM&#x02009;+) and women with ER-negative tumors who did not receive tamoxifen (ER&#x000a0;&#x02212;/TAM&#x000a0;&#x02212;) were eligible for cohort entry. In 2007, docetaxel was designated as guideline chemotherapy (in combination with cyclophosphamide and, for most, epirubicin [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]). Thus, we restricted the study population to women diagnosed from 2007 onwards for whom chemotherapy was recommended [<xref ref-type="bibr" rid="CR28">28</xref>] (&#x0feff;Supplementary file1, Supplemental Fig. 1). We included women aged 18&#x02013;55 years at diagnosis to ensure women were of working age throughout the study period. Finally, we restricted our sample to women with available FFPE tumor blocks who resided in Denmark during the year preceding diagnosis.</p><p id="Par29">The study was approved by the Danish Data Protection Agency (AU 2016-051-000001, #808), the Regional Ethics Committee (record no. 1-10-72-4-18), and the DBCG (DBCG-2018-01-04).</p></sec><sec id="Sec5"><title>Genetic variants in breast tumor tissue</title><p id="Par30">We investigated 21 candidate SNPs in 16 genes coding for enzymes involved in taxane metabolism (<italic>CYP1B1, CYP3A, CYP3A4, CYP3A5,</italic> and <italic>GSTP1</italic>), taxane transport (<italic>ABCB1, ABCC2, ABCG2, SLCO1B1,</italic> and <italic>SLCO1B3)</italic>, DNA repair (<italic>ERCC1</italic> and <italic>ERCC2),</italic> and taxane-related toxicity or neural repair (<italic>EPHA4, EPHA5, EPHA6,</italic> and <italic>FGD4</italic>) [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Archived breast tumor tissue blocks were collected for eligible ProBe CaRe participants. DNA was extracted and genotyped for the selected SNPs using commercially available TaqMan assays on a StepOne Plus real-time instrument (Applied Biosystems, Thermo Fischer Scientific, Foster City, CA, USA), as previously described [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. RefSeq numbers (rs) and assay details of the SNPs are provided in Supplementary file1, Supplementary Table&#x000a0;1.</p><p id="Par31">We categorized women based on number of variant alleles as non-carriers (carrying no variant allele on either locus) or carriers (carrying the variant on one locus [heterozygotes] or on both loci [homozygotes]) for each gene.</p></sec><sec id="Sec6"><title>Social benefit use</title><p id="Par32">We used the DREAM database, which contains weekly records of all transfer payments, to access information on receipt of social benefits. We collected information from 1 year before to 5 years after the breast cancer diagnosis date (i.e., date of breast cancer surgery). Given the diagnostic period of our study population (2007&#x02013;2011), we examined data on social benefits from 2006&#x02013;2016.</p><p id="Par33">Specifically for sick leave, only &#x02018;long-term&#x02019; leave is captured by DREAM [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Conversely, &#x02018;short-term&#x02019; sick leave is not registered. &#x02018;Short-term&#x02019; is defined as the initial period in which the employer must cover the cost of sick leave compensation, ranging from 14 to 30 days during our study period [<xref ref-type="bibr" rid="CR31">31</xref>]. Absence lasting longer than this period is defined as &#x02018;long-term&#x02019;. After the initial period, the employer is reimbursed by the municipality for the sick leave compensation, which is registered in DREAM [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. In addition, the initial period is also registered, and DREAM thus reflects the entire length of &#x02018;long-term&#x02019; sick leave (from the first day of absence).</p><p id="Par34">For each week, we categorized women into one of three social benefit categories: receiving health-related benefits, receiving labor market-related benefits, and self-supporting or receiving student grants (referred to as &#x02018;self-supporting&#x02019;; Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). We categorized women who received benefits due to maternity leave according to their social benefit category during the week immediately before the start of maternity leave. If women had retired, emigrated, or died they were placed into a fourth censored category. Full details of DREAM codes used for categorizing cohort members are provided in Supplementary file1, Supplementary Table&#x000a0;2.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Social benefit categories classified using the DREAM database</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Category</th><th align="left">Types of benefits</th></tr></thead><tbody><tr><td align="left" rowspan="5">Health-related benefits</td><td align="left">&#x02018;Long-term&#x02019; sick leave<sup>a</sup></td></tr><tr><td align="left">Disability pension</td></tr><tr><td align="left">Flexi job scheme (helping individuals with reduced ability to work and thus stay in the labor market [<xref ref-type="bibr" rid="CR32">32</xref>])</td></tr><tr><td align="left">Early retirement after flexi job</td></tr><tr><td align="left">Vocational rehabilitation programs and determination of work ability (often used before granting a disability pension)</td></tr><tr><td align="left" rowspan="2">Labor market-related benefits</td><td align="left">Unemployment, including part-time unemployment</td></tr><tr><td align="left">Social security/assistance</td></tr><tr><td align="left" rowspan="2">Self-supporting</td><td align="left">No benefit as proxy for employed or self-supporting</td></tr><tr><td align="left">Student grants and adult traineeships</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>&#x02018;Short-term&#x02019; sick leave is paid by the employer and thus not captured by DREAM.&#x000a0;During our study period, &#x02018;short-term&#x02019; sick leave ranged from 14 to 30&#x000a0;days [<xref ref-type="bibr" rid="CR31">31</xref>]</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec7"><title>Covariates</title><p id="Par35">Because CYP family genes are also involved in tamoxifen metabolism [<xref ref-type="bibr" rid="CR14">14</xref>], associations between SNPs and social benefit receipt could potentially be affected by ER-status and receipt of tamoxifen. We therefore used the DBCG database to ascertain data on ER-status and receipt of tamoxifen. Other covariates considered were age at diagnosis, additional clinical and treatment characteristics (including tumor stage, grade, HER2, type of surgery, and radiotherapy [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]), comorbidities categorized using the Charlson Comorbidity Index (CCI) Score [<xref ref-type="bibr" rid="CR33">33</xref>], cohabitation status (cohabiting; living alone), and the highest attained educational level at diagnosis (short [~&#x02009;9&#x02013;11 years of schooling]; intermediate [~&#x02009;12&#x02013;13 years of schooling]; long [~&#x02009;14&#x02013;20 years of schooling]).</p></sec><sec id="Sec8"><title>Statistical analysis</title><p id="Par36">Participant characteristics were described with frequencies and proportions.</p><p id="Par37">We visually described receipt of social benefits by plotting the proportion of women in each of the social benefit categories in weekly intervals.</p><p id="Par38">We estimated the association of SNPs with the number of weeks spent in each of the three social benefit categories (i.e., receiving health-related benefits, receiving labor market-related benefits, and self-supporting) and the associated rate ratio (RR), 95% confidence intervals (CI) and p-values using negative binominal regression models with a robust variance estimator. Differences in log counts between variant carriers and non-carriers can be interpreted as log RR when follow-up is constant. To account for differences in social benefit receipt by time period with respect to breast cancer diagnosis, we stratified all analyses by time (&#x02212;&#x000a0;12&#x02013;0, 1&#x02013;6, 7&#x02013;12, 13&#x02013;24, and 25&#x02013;60&#x000a0;months from the diagnosis date). We used unadjusted models because variant alleles are allocated randomly at conception and thus causally unrelated to covariates. We used volcano plots (&#x02212;&#x02009;log(p) against RR) to visually summarize the results. To represent the uncertainty of the RR, we plotted the ratio between the upper and lower limit of the 95% CI (UL/LL) against the RR; a smaller ratio represents a narrower CI.</p><p id="Par39">In exploratory analyses, we ran the same models separately for heterozygotes and homozygotes compared with non-carriers. Because of the low minor allele frequency of some SNPs and resulting low statistical power, we only report results for SNPs with at least 100 homozygous variant women. We also repeated the main analyses in women in the ER&#x02009;+/TAM&#x02009;+ group.</p><p id="Par40">All analyses were conducted using SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA).</p></sec></sec><sec id="Sec9"><title>Results</title><p id="Par41">The study population included 2430 women after exclusions (Supplementary file1, Supplementary Fig.&#x000a0;1). Most women were diagnosed at ages 45&#x02013;55 years (56%), with tumors that were ER&#x02009;+&#x02009;(78%), HER2 negative (75%), stage II (56%), and grade 2 (42%) or 3 (33%) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Treatment most often included lumpectomy (61%), and all women with ER&#x02009;+&#x02009;tumors received tamoxifen. Most had a comorbidity score of zero (87%), were living with a partner (76%), and had completed an intermediate (48%) or long (34%) education.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Characteristics of 2430 premenopausal women with breast cancer who were intended to receive treatment with docetaxel in Denmark (2007&#x02013;2011)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristics</th><th align="left">N</th><th align="left">%<sup>a</sup></th></tr></thead><tbody><tr><td align="left">Total</td><td align="left">2430</td><td align="left">100</td></tr><tr><td align="left">Age at diagnosis, years</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;18&#x02013;34</td><td align="left">172</td><td align="left">7</td></tr><tr><td align="left">&#x000a0;35&#x02013;44</td><td align="left">901</td><td align="left">37</td></tr><tr><td align="left">&#x000a0;45&#x02013;55</td><td align="left">1357</td><td align="left">56</td></tr><tr><td align="left">ER-status and endocrine therapy</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;ER&#x02013;/TAM&#x02013;</td><td align="left">535</td><td align="left">22</td></tr><tr><td align="left">&#x000a0;ER&#x02009;+/TAM&#x02009;+&#x02009;</td><td align="left">1895</td><td align="left">78</td></tr><tr><td align="left">HER2 status</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Negative</td><td align="left">1820</td><td align="left">75</td></tr><tr><td align="left">&#x000a0;Positive</td><td align="left">447</td><td align="left">18</td></tr><tr><td align="left">&#x000a0;Unknown</td><td align="left">163</td><td align="left">7</td></tr><tr><td align="left">Stage</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Stage I</td><td align="left">619</td><td align="left">26</td></tr><tr><td align="left">&#x000a0;Stage II</td><td align="left">1367</td><td align="left">56</td></tr><tr><td align="left">&#x000a0;Stage III</td><td align="left">426</td><td align="left">18</td></tr><tr><td align="left"> Missing</td><td align="left">18</td><td align="left">1</td></tr><tr><td align="left">Histological grade</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Grade 1</td><td align="left">364</td><td align="left">15</td></tr><tr><td align="left">&#x000a0;Grade 2</td><td align="left">1010</td><td align="left">42</td></tr><tr><td align="left">&#x000a0;Grade 3</td><td align="left">798</td><td align="left">33</td></tr><tr><td align="left">&#x000a0;Not graded</td><td align="left">229</td><td align="left">9</td></tr><tr><td align="left">&#x000a0;Missing</td><td align="left">29</td><td align="left">1</td></tr><tr><td align="left">Surgery and radiotherapy</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Mastectomy without intended radiotherapy</td><td align="left">327</td><td align="left">14</td></tr><tr><td align="left">&#x000a0;Mastectomy and intended radiotherapy</td><td align="left">615</td><td align="left">25</td></tr><tr><td align="left">&#x000a0;Lumpectomy</td><td align="left">1488</td><td align="left">61</td></tr><tr><td align="left">Comorbidity, CCI score</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;0</td><td align="left">2108</td><td align="left">87</td></tr><tr><td align="left">&#x000a0;1</td><td align="left">165</td><td align="left">7</td></tr><tr><td align="left">&#x000a0;2</td><td align="left">70</td><td align="left">3</td></tr><tr><td align="left">&#x000a0;3&#x02009;+&#x02009;</td><td align="left">87</td><td align="left">4</td></tr><tr><td align="left">Cohabitation</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Cohabiting</td><td align="left">1857</td><td align="left">76</td></tr><tr><td align="left">&#x000a0;Living alone</td><td align="left">566</td><td align="left">23</td></tr><tr><td align="left">&#x000a0;Unknown</td><td align="left">7</td><td align="left">0</td></tr><tr><td align="left">Education level</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Short (~&#x02009;9&#x02013;11&#x000a0;years of schooling)</td><td align="left">412</td><td align="left">17</td></tr><tr><td align="left">&#x000a0;Intermediate (~&#x02009;12&#x02013;13&#x000a0;years of schooling)</td><td align="left">1164</td><td align="left">48</td></tr><tr><td align="left">&#x000a0;Long (~&#x02009;14&#x02013;20&#x000a0;years of schooling)</td><td align="left">826</td><td align="left">34</td></tr><tr><td align="left">&#x000a0;Unknown</td><td align="left">28</td><td align="left">1</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Percentages may not add to 100% because of rounding</p><p><italic>CCI</italic> Charlson Comorbidity Index [<xref ref-type="bibr" rid="CR33">33</xref>], <italic>ER</italic> estrogen receptor, <italic>ER&#x02009;+/TAM&#x02009;+</italic> women with ER-positive tumors who received tamoxifen, <italic>ER&#x000a0;&#x02212;/TAM&#x000a0;&#x02212;</italic> women with ER-negative tumors who did not receive tamoxifen, <italic>HER2</italic> human epidermal growth factor receptor 2</p></table-wrap-foot></table-wrap></p><sec id="Sec10"><title>Receipt of social benefits</title><p id="Par42">Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> shows social benefit receipt, from 1 year before to 5 years after breast cancer diagnosis, in the entire study population regardless of genetic variants. Percentages of women in each social benefit category 1 year before diagnosis, at diagnosis, and at the end of the 6th, 12th, 24th, and 60th month after diagnosis are shown in &#x0feff;Supplementary file2, Supplementary Table&#x000a0;3. One year before diagnosis, 12% received health-related benefits and 6% received labor market-related benefits, while 82% were self-supporting. As expected, the proportion of women receiving health-related benefits increased markedly from a few weeks prior to diagnosis to the diagnosis date, at which point 80% of women received health-related benefits, 3% received labor market-related benefits, and 18% were self-supporting. This pattern was observed until six months after diagnosis, the period during which patients typically undergo surgery, chemotherapy, and radiotherapy. From 6 to 24 months after diagnosis, receipt of social benefits fell, driven by fewer women receiving health-related benefits (26% at the end of the 24th month). From then onwards, the pattern stabilized with approximately 23% receiving health-related benefits. In the same period, 6% received labor market-related social benefits and 65% were self-supporting.<fig id="Fig1"><label>Fig. 1</label><caption><p>Percent of women receiving social benefits from 1 year prior to 5 years after breast cancer diagnosis among 2430 premenopausal women with breast cancer in Denmark (2007&#x02013;2011). Details of the categorization are available in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and in &#x0feff;Supplementary file1, Supplementary Table&#x000a0;2</p></caption><graphic xlink:href="10549_2024_7474_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec11"><title>Genetic variants and receipt of social benefits</title><p id="Par43">Overall, we found no compelling evidence of associations between the examined SNPs and receipt of social benefits. However, associations between eight SNPs and receipt of social benefits stood out at one or more time periods for at least one of the social benefit groups (Figs.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, <xref rid="Fig3" ref-type="fig">3</xref> and <xref rid="Fig4" ref-type="fig">4</xref>), namely <italic>CYP3A</italic> rs10273424, <italic>CYP3A4</italic> rs2740574, <italic>CYP3A5</italic> rs776746, <italic>GSTP1</italic> rs1138272, <italic>EPHA4</italic> rs17348202, <italic>EPHA6</italic> rs301927, <italic>ERCC1</italic> rs3212986, and <italic>FGD4</italic> rs10771973.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Associations between 21 SNPs and receipt of <italic>health-related benefits</italic> among 2430 premenopausal women with breast cancer in Denmark from 1 year before to 5 years after diagnosis (2007&#x02013;2011). <bold>a</bold> Volcano plot:&#x02009;&#x02212;&#x000a0;&#x02009;log(<italic>p</italic>) against the rate ratio. <bold>b</bold> Volcano plot: Ratio of the 95% CI upper and lower limit against the rate ratio. <italic>CI</italic> Confidence interval, <italic>RR</italic> rate ratio, <italic>SNP</italic> single nucleotide polymorphism, <italic>UL/LL</italic> the ratio between the upper and lower limit of the 95% confidence interval. Estimates are for variant carriers compared with non-carriers. Numbered labels refer to the time period in months since breast cancer diagnosis. We colored and labelled SNPs that stood out during at least one time period<bold>.</bold> A smaller UL/LL reflects a narrower confidence interval. Full results are available in Supplementary file2, Supplementary Table&#x000a0;4</p></caption><graphic xlink:href="10549_2024_7474_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Associations between 21 SNPs and receipt of <italic>labor market-related benefits</italic> among 2430 premenopausal women with breast cancer in Denmark from 1 year before to 5 years after diagnosis (2007&#x02013;2011). <bold>a</bold> Volcano plot:&#x02009;&#x02212;&#x000a0;&#x02009;log(<italic>p</italic>) against the rate ratio. <bold>b</bold> Volcano plot: Ratio of the 95% CI upper and lower limit against the rate ratio. <italic>CI</italic> Confidence interval, <italic>RR</italic> rate ratio, <italic>SNP</italic> single nucleotide polymorphism, <italic>UL/LL</italic> the ratio between the upper and lower limit of the 95% confidence interval. Estimates are for variant carriers compared with non-carriers. Numbered labels refer to the time period in months since breast cancer diagnosis. We colored and labelled SNPs that stood out during&#x000a0;at least one time period<bold>.</bold> A smaller UL/LL reflects a narrower confidence interval. NB: the scale on the y-axis of panel B differs from that of panel B in Figs.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> and <xref rid="Fig4" ref-type="fig">4</xref>. Full results are available in Supplementary file2, Supplementary Table&#x000a0;5</p></caption><graphic xlink:href="10549_2024_7474_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Associations between 21 SNPs and <italic>self-support</italic> among 2430 premenopausal women with breast cancer in Denmark from 1 year before to 5 years after diagnosis (2007&#x02013;2011). <bold>a</bold> Volcano plot:&#x02009;&#x02212;&#x000a0;log(<italic>p</italic>) against the rate ratio<bold>. b</bold> Volcano plot: Ratio of the 95% CI upper and lower limit against the rate ratio. <italic>CI</italic> Confidence interval, <italic>RR</italic> rate ratio, <italic>SNP</italic> single nucleotide polymorphism, <italic>UL/LL</italic> the ratio between the upper and lower limit of the 95% confidence interval. Estimates are for variant carriers compared with non-carriers. Numbered labels refer to the time period in months since breast cancer diagnosis. We colored and labelled SNPs that stood out during at least one time period. A smaller UL/LL reflects a narrower confidence interval. Full results are available in &#x0feff;Supplementary file2, Supplementary Table&#x000a0;6</p></caption><graphic xlink:href="10549_2024_7474_Fig4_HTML" id="MO4"/></fig></p><sec id="Sec12"><title>Health-related benefits</title><p id="Par44">Variant carriers of <italic>GSTP1</italic> rs1138272 (<italic>n</italic>&#x02009;=&#x02009;365) were slightly more likely to receive health-related benefits than non-carriers from diagnosis until 24 months after diagnosis (RRs [95% CIs]: 1.04 [0.99, 1.08], 1.06 [1.00, 1.13], and 1.12 [0.99, 1.28] during 1&#x02013;6, 7&#x02013;12, and 13&#x02013;24 months, respectively; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>; Supplementary file2, Supplementary Table&#x000a0;4). RRs and differences in the median number of weeks on health-related benefits were small. A similar pattern was observed for variant carriers of <italic>FGD4</italic> rs10771973 (<italic>n</italic>&#x02009;=&#x02009;1169) from 7 to 60 months after diagnosis (RRs 1.04 [0.99, 1.09], 1.07 [0.97, 1.18], and 1.08 [0.95, 1.24] during 7&#x02013;12, 13&#x02013;24, and 25&#x02013;60 months, respectively), but also in the year before diagnosis (RR: 1.11 [0.94, 1.32]).</p><p id="Par45">Variant carriers of <italic>CYP3A</italic> rs10273424 (<italic>n</italic>&#x02009;=&#x02009;398) received health-related benefits less often than non-carriers during 13&#x02013;24 months after diagnosis (RR 0.84 [0.72, 0.97]; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>; Supplementary file2, Supplementary Table&#x000a0;4). The same applied to variant carriers of <italic>EPHA4</italic> rs17348202 (<italic>n</italic>&#x02009;=&#x02009;231) in the six months directly following diagnosis (RR 0.92 [0.86, 0.98]). For <italic>CYP3A</italic> rs10273424, the median number of weeks of health-related benefits received during 13&#x02013;24 months post-diagnosis was 3 (inter-quartile range [IQR]: 0, 26 weeks) for variant carriers and 6 (IQR 0, 35 weeks) for non-carriers. The corresponding number of weeks for <italic>EPHA4</italic> rs17348202 during 1&#x02013;6 months were 26 (IQR 20, 26 weeks) and 26 (IQR 26, 26 weeks).</p></sec><sec id="Sec13"><title>Labor market-related benefits</title><p id="Par46">Receipt of labor market-related benefits was uncommon. The median number of weeks was 0 (IQR 0, 0 weeks) for all time periods in both carriers and non-carriers, except for variant carriers of <italic>CYP3A5</italic> rs776746 (<italic>n</italic>&#x02009;=&#x02009;332) during 25&#x02013;60 months post-diagnosis (0 [0, 5] weeks; Supplementary file2, Supplementary Table&#x000a0;5). While we observed relatively strong RR estimates between some SNPs and receipt of labor market-related benefits, confidence intervals were wide (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>; Supplementary file2, Supplementary Table&#x000a0;5).</p></sec><sec id="Sec14"><title>Self-support</title><p id="Par47">Carriers of <italic>CYP3A</italic> rs10273424 (<italic>n</italic>&#x02009;=&#x02009;398) were more likely to be self-supporting 13&#x02013;24 months after diagnosis than non-carriers (RR 1.10 [1.03, 1.18]; Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>; &#x0feff;Supplementary file2, Supplementary Table&#x000a0;6). The median number of weeks of self-support was 47 (IQR 12, 52 weeks) for variant carriers vs. 41 (IQR 2, 52 weeks) for non-carriers. Compared with non-carriers, during 1&#x02013;6 months after diagnosis, we observed positive associations for self-support among variant carriers of <italic>CYP3A5</italic> rs776746 (<italic>n</italic>&#x02009;=&#x02009;332; RR 1.18 [0.92, 1.53]) and <italic>EPHA4</italic> rs17348202 (<italic>n</italic>&#x02009;=&#x02009;231; RR 1.33 [1.00, 1.76]), and an inverse association for <italic>ERCC1</italic> rs3212986 (<italic>n</italic>&#x02009;=&#x02009;967; RR 0.84 [0.69, 1.03]). However, few women were self-supporting during this period, with a median of 0 (IQR: 0, 0) weeks for all three SNPs in both carriers and non-carriers.</p></sec><sec id="Sec15"><title>Exploratory analyses</title><p id="Par48">Results were not meaningfully changed for heterozygous or homozygous women (Supplementary file2, Supplementary Tables 4&#x02013;6), nor in analyses restricted to women in the ER&#x02009;+/TAM&#x02009;+&#x02009;group (<italic>n</italic>&#x02009;=&#x02009;1895; &#x0feff;Supplementary file2, Supplementary Tables 7&#x02013;9).</p></sec></sec></sec><sec id="Sec16"><title>Discussion</title><p id="Par49">In this study of social benefit receipt from 1 year before through 5 years after breast cancer diagnosis, we found that approximately 80% of premenopausal breast cancer patients received health-related social benefits in the first six months after diagnosis. This percentage declined over the next six months, stabilizing at approximately 23% for the period 2&#x02013;5 years after diagnosis, i.e., nearly&#x000a0;a doubling in the proportion from the year before breast cancer diagnosis. These results are comparable with those of studies conducted in Sweden, which reported that 60% of breast cancer survivors were on sick leave shortly after diagnosis [<xref ref-type="bibr" rid="CR7">7</xref>], and that 71% were on sick leave during the first year after diagnosis [<xref ref-type="bibr" rid="CR34">34</xref>]. Proportions of breast cancer survivors on sick leave declined considerably over time, reaching 13%, 2 years after diagnosis [<xref ref-type="bibr" rid="CR7">7</xref>] and 19%, 5 years after diagnosis [<xref ref-type="bibr" rid="CR34">34</xref>]. Receipt of disability pension was relatively stable over time in the Swedish study, with 21&#x02013;24% receiving a disability pension during the first to fifth year after diagnosis [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par50">We found no evidence that the 21 candidate SNPs related to taxane metabolism, transport, toxicity, and DNA and neural repair were meaningfully associated with receipt of social benefits. Although associations for eight SNPs were suggested, estimates were close to null and/or imprecise due to low numbers. Variant carriers of <italic>CYP3A</italic> rs10273424 were at slightly lower risk of receiving health-related benefits and more likely to be self-supporting during the second year after diagnosis. Our previous findings for the ProBe CaRe cohort suggested that carriers compared with non-carriers of this SNP were more likely to return-to-work and to achieve stable attachment to the labor market within the first 2 years following breast cancer diagnosis [<xref ref-type="bibr" rid="CR15">15</xref>]. However, in the same cohort, carriers of this variant had a higher risk of dying after a breast cancer diagnosis than non-carriers (hazard ratio [95% CIs]: 1.33 [0.98, 1.81]) [<xref ref-type="bibr" rid="CR29">29</xref>]. The possible mechanisms underlying these findings are not clear. Although <italic>CYP3A</italic> rs10273424 is an intronic variant (i.e., non-coding), it could act via modified splicing or linkage disequilibrium with other SNPs [<xref ref-type="bibr" rid="CR29">29</xref>]. Nevertheless, we cannot rule out chance. Furthermore, we observed that variant carriers of <italic>GSTP1</italic> rs1138272 and <italic>FGD4</italic> rs10771973 had marginally higher rates of health-related benefits than non-carriers after breast cancer diagnosis. Although this is in line with studies reporting associations between these SNPs and higher risk of taxane-induced peripheral neuropathy in variant carriers than non-carriers [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>], lack of replication is a pertinent issue [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. For <italic>FGD4</italic> rs10771973, we also observed an association in the year before diagnosis, and thereby before chemotherapy. Thus, differential toxicity of taxane-based chemotherapy between variant carriers and non-carriers is unlikely to explain our findings for this SNP. Larger studies are needed to robustly estimate the possible associations between the selected SNPs and receipt of social benefits, and the underlying mechanisms and any link to ability to work should be explored.</p><p id="Par51">Given the lack of evidence of associations between the selected SNPs and social benefit receipt, other avenues for supporting women&#x02019;s labor market attachment after breast cancer, should be considered. A recent analysis in our cohort found a social gradient in receipt of health-related benefits by level of education and cohabitation status [<xref ref-type="bibr" rid="CR30">30</xref>]. Therefore, efforts to increase labor market attachment in survivors of breast cancer with short education and living alone may prove valuable.</p><p id="Par52">The main strength of this study was its high-quality data and complete follow-up, limiting selection and information biases. The high-quality of the data stemmed from (i) using a population-based cohort identified from the DBCG database with high validity [<xref ref-type="bibr" rid="CR26">26</xref>]; (ii) accessing detailed weekly registry-based data on social benefit payments from the DREAM database, which has previously been validated and regarded as suitable for health research [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]; and (iii) applying extensive quality control to the SNP data [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Only for <italic>CYP1B1</italic> rs1056836 were the observed and expected genotype frequencies meaningfully different (Supplementary file1, Supplementary Table&#x000a0;1).</p><p id="Par53">Our study also had several limitations. First, we had no information on whether receiving health-related social benefits was related to taxane treatment or not. Furthermore, we used recommended chemotherapy rather than administered chemotherapy to avoid immortal time bias [<xref ref-type="bibr" rid="CR37">37</xref>]. We also lacked information on dose, dose-reduction, discontinuation, and adverse effects of chemotherapy. Women experiencing side effects from chemotherapy, potentially due to genetic predisposition, might have received lower doses of chemotherapy, paused or discontinued their treatment. This could potentially lead to underestimation of the association between the selected SNPs and receipt of social benefits. In addition, docetaxel was given in combination with cyclophosphamide and for most patients, with epirubicin. Chemotherapy was followed by endocrine therapy for women with ER&#x02009;+&#x02009;tumors, and tamoxifen metabolism is also affected by genes of the CYP family [<xref ref-type="bibr" rid="CR14">14</xref>]. For these reasons, we cannot necessarily assign any potential effect fully to docetaxel. Second, while we have accounted for time since breast cancer diagnosis, we have not accounted for changes in the general Danish economy, including unemployment rates and the legislation on social benefits. Such changes are, however, unlikely to impact our estimates of the associations between SNPs and social benefit receipt, assuming that the distributions of the SNPs are stable over time. Finally, we studied each SNP separately without considering their combined effect. Moreover, we genotyped DNA obtained from tumor tissue, which may not perfectly reflect the genotype influencing enzyme activity in the liver where docetaxel is metabolized. Nonetheless, earlier studies have reported excellent agreement between genotype for breast cancer patients ascertained in DNA from FFPE tumor tissue, and from both FFPE non-cancerous lymph node tissue [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>] and full blood leukocytes representing germline mutations [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p id="Par54">In conclusion, we found no evidence of clinically meaningful associations between selected SNPs related to taxane metabolism, transport, toxicity, or DNA and neural repair, and receipt of social benefits among premenopausal breast cancer survivors.</p></sec><sec id="Sec17" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="10549_2024_7474_MOESM1_ESM.pdf"><caption><p>Supplementary file1 (PDF 268 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="10549_2024_7474_MOESM2_ESM.xlsx"><caption><p>Supplementary file2 (XLSX 74 KB)</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CCI</term><def><p id="Par5">Charlson Comorbidity Index</p></def></def-item><def-item><term>CI</term><def><p id="Par6">Confidence interval</p></def></def-item><def-item><term>DBCG</term><def><p id="Par7">Danish Breast Cancer Group</p></def></def-item><def-item><term>DREAM</term><def><p id="Par8">Danish Register for Evaluation of Marginalization</p></def></def-item><def-item><term>ER</term><def><p id="Par9">Estrogen receptor</p></def></def-item><def-item><term>ER&#x02009;+&#x02009;/TAM&#x02009;+&#x02009;</term><def><p id="Par10">Women with ER-positive tumors who received tamoxifen</p></def></def-item><def-item><term>ER&#x000a0;&#x02212;/TAM&#x000a0;&#x02212;</term><def><p id="Par11">Women with ER-negative tumors who did not receive tamoxifen</p></def></def-item><def-item><term>FFPE</term><def><p id="Par12">Formalin-fixed paraffin-embedded</p></def></def-item><def-item><term>HER2</term><def><p id="Par13">Human epidermal growth factor receptor 2</p></def></def-item><def-item><term>IQR</term><def><p id="Par14">Inter-quartile range</p></def></def-item><def-item><term>ProBe CaRe</term><def><p id="Par15">Predictors of Breast Cancer Recurrence</p></def></def-item><def-item><term>RR</term><def><p id="Par16">Rate ratio</p></def></def-item><def-item><term>rs</term><def><p id="Par17">RefSeq</p></def></def-item><def-item><term>SNP</term><def><p id="Par18">Single nucleotide polymorphisms</p></def></def-item><def-item><term>UL/LL</term><def><p id="Par19">Ratio between the upper and lower limit of the 95% confidence interval</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank the Danish Breast Cancer Group for providing the clinical data and the laboratory personnel for assisting with tumor tissue procurement, DNA extraction, and genotyping.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>CRediT Contributor Roles Taxonomy (niso.org). Conceptualization: J.A.S., C.F.H., and D.C.-F.; Data curation: D.K.F.; Formal analysis: D.K.F.; Funding acquisition: C.F.H. and D.C.-F.; Investigation: J.A.S., C.F.H., P.D., S.F., S.H.-D., B.E., and D.C.-F.; Methodology J.A.S., C.F.H., D.K.F, T.L.L., T.P.A., and D.C.-F.; Project admin: J.A.S.; Resources: P.D., S.F., S.H&#x02013;D., and B.E.; Softwear: D.K.F.; Supervision: D.C.-F.; Validation: J.A.S. and D.K.F.; Visualization: J.A.S. and D.K.F.; Writing&#x02014;original draft: J.A.S.; Writing&#x02014;review &#x00026; editing: all authors.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by Aarhus Universitet. This work was supported by grants from the Novo Nordisk Foundation (NNF19OC0058710 to D.C.-F.), the Danish Cancer Society (R327-A19070 and R167-A11045-17 to D.C.-F., and travel grant R359-A21368 to J.A.S.), the Danish Cancer Research Foundation (FID1839672 to C.F.H.), and the Lundbeck Foundation (R167-2013-15861 to D.C.-F.). The ProBe CaRe cohort infrastructure was supported by the US National Cancer Institute (R01CA166825 to T.L.L.). The funders played no role in the study design, in the collection, analysis, and interpretation of data, in the writing of the manuscript, or in the decision to submit the manuscript for publication.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data used in our analyses for this paper cannot be shared, in accordance with Danish law. The data is not publicly accessible and is stored on servers at Statistics Denmark. The study protocol and statistical analysis plan are available upon request to the authors.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par55">J.A.S., C.F.H., D.K.F, S.F., S.H.-D., T.P.A, and D.C.-F. declare no competing interests. P.D. is an Internal employee health care consultant at Fertin Pharma A/S. B.E. discloses the following: Institutional grants from: Astra Zeneca, Daiichi Sankyo, Eli Lilly, Merck, Novartis, Pfizer, and Samsung. Advisory board: Eli Lilly. Travel grants: Daiichi Sankyo and Merck. T.L.L. participates in the Amgen Inc. Methods Advisory Council, for which he receives consulting fees and travel support. The Department of Clinical Epidemiology, Aarhus University, receives funding for other studies from the European Medicines Agency and from companies in the form of research grants to and administered by Aarhus University. None of these disclosures have any relation to the present study.</p></notes><notes id="FPar2"><title>Ethical approval</title><p id="Par56">The study was conducted in line with the principle of the Declaration of Helsinki. It was approved by the Danish Data Protection Agency (AU 2016&#x02013;051-000001, #808), the Regional Ethics Committee (record no. 1&#x02013;10-72&#x02013;4-18), and the Danish Breast Cancer Group (DBCG-2018&#x02013;01-04).</p></notes><notes id="FPar3"><title>Consent to participant</title><p id="Par57">Due to the use of archival tissue and registry-based data, informed consent from the participants was not required.</p></notes><notes id="FPar4"><title>Consent for publcation</title><p id="Par58">No individual-level data are displayed in this publication and consent to publish is thus not applicable.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name></person-group><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2021</year><volume>71</volume><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209&#x02013;249. 10.3322/caac.21660<pub-id pub-id-type="pmid">33538338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pi&#x000f1;eros M, Znaor A, Soerjomataram I, Bray F (2020) Global cancer observatory: cancer today. <ext-link ext-link-type="uri" xlink:href="https://gco.iarc.fr/today">https://gco.iarc.fr/today</ext-link>. Accessed 14 Feb 2022</mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>J</given-names></name><name><surname>Ajani</surname><given-names>J</given-names></name><name><surname>Scott&#x000e9;</surname><given-names>F</given-names></name><name><surname>Winther</surname><given-names>D</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Aapro</surname><given-names>MS</given-names></name><name><surname>von Minckwitz</surname><given-names>G</given-names></name></person-group><article-title>Docetaxel-related side effects and their management</article-title><source>Eur J Oncol Nurs</source><year>2009</year><volume>13</volume><fpage>49</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.ejon.2008.10.003</pub-id><pub-id pub-id-type="pmid">19201649</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Baker J, Ajani J, Scott&#x000e9; F, Winther D, Martin M, Aapro MS, von Minckwitz G (2009) Docetaxel-related side effects and their management. Eur J Oncol Nurs 13:49&#x02013;59. 10.1016/j.ejon.2008.10.003<pub-id pub-id-type="pmid">19201649</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Eckhoff</surname><given-names>L</given-names></name><name><surname>Nielsen</surname><given-names>M</given-names></name><name><surname>Moeller</surname><given-names>S</given-names></name><name><surname>Knoop</surname><given-names>A</given-names></name></person-group><article-title>TAXTOX&#x02014;a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009</article-title><source>Acta Oncol</source><year>2011</year><volume>50</volume><fpage>1075</fpage><lpage>1082</lpage><pub-id pub-id-type="doi">10.3109/0284186x.2011.602111</pub-id><pub-id pub-id-type="pmid">21824038</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Eckhoff L, Nielsen M, Moeller S, Knoop A (2011) TAXTOX&#x02014;a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009. Acta Oncol 50:1075&#x02013;1082. 10.3109/0284186x.2011.602111<pub-id pub-id-type="pmid">21824038</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Ewertz</surname><given-names>M</given-names></name><name><surname>Qvortrup</surname><given-names>C</given-names></name><name><surname>Eckhoff</surname><given-names>L</given-names></name></person-group><article-title>Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives</article-title><source>Acta Oncol</source><year>2015</year><volume>54</volume><fpage>587</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.3109/0284186x.2014.995775</pub-id><pub-id pub-id-type="pmid">25751757</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Ewertz M, Qvortrup C, Eckhoff L (2015) Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol 54:587&#x02013;591. 10.3109/0284186x.2014.995775<pub-id pub-id-type="pmid">25751757</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Plym</surname><given-names>A</given-names></name><name><surname>Johansson</surname><given-names>ALV</given-names></name><name><surname>Bower</surname><given-names>H</given-names></name><name><surname>Wennstig</surname><given-names>AK</given-names></name><name><surname>Fredriksson</surname><given-names>I</given-names></name><name><surname>Ahlgren</surname><given-names>J</given-names></name><name><surname>Lambe</surname><given-names>M</given-names></name></person-group><article-title>Impact of chemotherapy, radiotherapy, and endocrine therapy on sick leave in women with early-stage breast cancer during a 5-year period: a population-based cohort study</article-title><source>Breast Cancer Res Treat</source><year>2020</year><volume>182</volume><fpage>699</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1007/s10549-020-05720-4</pub-id><pub-id pub-id-type="pmid">32506337</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Plym A, Johansson ALV, Bower H, Wennstig AK, Fredriksson I, Ahlgren J, Lambe M (2020) Impact of chemotherapy, radiotherapy, and endocrine therapy on sick leave in women with early-stage breast cancer during a 5-year period: a population-based cohort study. Breast Cancer Res Treat 182:699&#x02013;707. 10.1007/s10549-020-05720-4<pub-id pub-id-type="pmid">32506337</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Petersson</surname><given-names>LM</given-names></name><name><surname>Vaez</surname><given-names>M</given-names></name><name><surname>Nilsson</surname><given-names>MI</given-names></name><name><surname>Saboonchi</surname><given-names>F</given-names></name><name><surname>Alexanderson</surname><given-names>K</given-names></name><name><surname>Olsson</surname><given-names>M</given-names></name><name><surname>Wennman-Larsen</surname><given-names>A</given-names></name></person-group><article-title>Sickness absence following breast cancer surgery: a two-year follow-up cohort study</article-title><source>Scand J Caring Sci</source><year>2018</year><volume>32</volume><fpage>715</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1111/scs.12502</pub-id><pub-id pub-id-type="pmid">29048131</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Petersson LM, Vaez M, Nilsson MI, Saboonchi F, Alexanderson K, Olsson M, Wennman-Larsen A (2018) Sickness absence following breast cancer surgery: a two-year follow-up cohort study. Scand J Caring Sci 32:715&#x02013;724. 10.1111/scs.12502<pub-id pub-id-type="pmid">29048131</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>ME</given-names></name><name><surname>Scherer</surname><given-names>S</given-names></name><name><surname>Wiskemann</surname><given-names>J</given-names></name><name><surname>Steindorf</surname><given-names>K</given-names></name></person-group><article-title>Return to work after breast cancer: the role of treatment-related side effects and potential impact on quality of life</article-title><source>Eur J Cancer Care (Engl)</source><year>2019</year><volume>28</volume><fpage>e13051</fpage><pub-id pub-id-type="doi">10.1111/ecc.13051</pub-id><pub-id pub-id-type="pmid">31033073</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Schmidt ME, Scherer S, Wiskemann J, Steindorf K (2019) Return to work after breast cancer: the role of treatment-related side effects and potential impact on quality of life. Eur J Cancer Care (Engl) 28:e13051. 10.1111/ecc.13051<pub-id pub-id-type="pmid">31033073</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>van Egmond</surname><given-names>MP</given-names></name><name><surname>Duijts</surname><given-names>SFA</given-names></name><name><surname>Loyen</surname><given-names>A</given-names></name><name><surname>Vermeulen</surname><given-names>SJ</given-names></name><name><surname>van der Beek</surname><given-names>AJ</given-names></name><name><surname>Anema</surname><given-names>JR</given-names></name></person-group><article-title>Barriers and facilitators for return to work in cancer survivors with job loss experience: a focus group study</article-title><source>Eur J Cancer Care (Engl)</source><year>2017</year><pub-id pub-id-type="doi">10.1111/ecc.12420</pub-id><pub-id pub-id-type="pmid">26603683</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">van Egmond MP, Duijts SFA, Loyen A, Vermeulen SJ, van der Beek AJ, Anema JR (2017) Barriers and facilitators for return to work in cancer survivors with job loss experience: a focus group study. Eur J Cancer Care (Engl). 10.1111/ecc.12420<pub-id pub-id-type="pmid">26603683</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Baldwin</surname><given-names>RM</given-names></name><name><surname>Owzar</surname><given-names>K</given-names></name><name><surname>Zembutsu</surname><given-names>H</given-names></name><name><surname>Chhibber</surname><given-names>A</given-names></name><name><surname>Kubo</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Watson</surname><given-names>D</given-names></name><name><surname>Eclov</surname><given-names>RJ</given-names></name><name><surname>Mefford</surname><given-names>J</given-names></name><name><surname>McLeod</surname><given-names>HL</given-names></name><name><surname>Friedman</surname><given-names>PN</given-names></name><name><surname>Hudis</surname><given-names>CA</given-names></name><name><surname>Winer</surname><given-names>EP</given-names></name><name><surname>Jorgenson</surname><given-names>EM</given-names></name><name><surname>Witte</surname><given-names>JS</given-names></name><name><surname>Shulman</surname><given-names>LN</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Ratain</surname><given-names>MJ</given-names></name><name><surname>Kroetz</surname><given-names>DL</given-names></name></person-group><article-title>A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101</article-title><source>Clin Cancer Res</source><year>2012</year><volume>18</volume><fpage>5099</fpage><lpage>5109</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.Ccr-12-1590</pub-id><pub-id pub-id-type="pmid">22843789</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL (2012) A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 18:5099&#x02013;5109. 10.1158/1078-0432.Ccr-12-1590<pub-id pub-id-type="pmid">22843789</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Boora</surname><given-names>GK</given-names></name><name><surname>Kulkarni</surname><given-names>AA</given-names></name><name><surname>Kanwar</surname><given-names>R</given-names></name><name><surname>Beyerlein</surname><given-names>P</given-names></name><name><surname>Qin</surname><given-names>R</given-names></name><name><surname>Banck</surname><given-names>MS</given-names></name><name><surname>Ruddy</surname><given-names>KJ</given-names></name><name><surname>Pleticha</surname><given-names>J</given-names></name><name><surname>Lynch</surname><given-names>CA</given-names></name><name><surname>Behrens</surname><given-names>RJ</given-names></name><name><surname>Z&#x000fc;chner</surname><given-names>S</given-names></name><name><surname>Loprinzi</surname><given-names>CL</given-names></name><name><surname>Beutler</surname><given-names>AS</given-names></name></person-group><article-title>Association of the Charcot&#x02013;Marie-tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (alliance)</article-title><source>J Neurol Sci</source><year>2015</year><volume>357</volume><fpage>35</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2015.06.056</pub-id><pub-id pub-id-type="pmid">26143528</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Boora GK, Kulkarni AA, Kanwar R, Beyerlein P, Qin R, Banck MS, Ruddy KJ, Pleticha J, Lynch CA, Behrens RJ, Z&#x000fc;chner S, Loprinzi CL, Beutler AS (2015) Association of the Charcot&#x02013;Marie-tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (alliance). J Neurol Sci 357:35&#x02013;40. 10.1016/j.jns.2015.06.056<pub-id pub-id-type="pmid">26143528</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Eckhoff</surname><given-names>L</given-names></name><name><surname>Feddersen</surname><given-names>S</given-names></name><name><surname>Knoop</surname><given-names>AS</given-names></name><name><surname>Ewertz</surname><given-names>M</given-names></name><name><surname>Bergmann</surname><given-names>TK</given-names></name></person-group><article-title>Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer</article-title><source>Acta Oncol</source><year>2015</year><volume>54</volume><fpage>530</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.3109/0284186x.2014.969846</pub-id><pub-id pub-id-type="pmid">25383449</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Eckhoff L, Feddersen S, Knoop AS, Ewertz M, Bergmann TK (2015) Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer. Acta Oncol 54:530&#x02013;537. 10.3109/0284186x.2014.969846<pub-id pub-id-type="pmid">25383449</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Kus</surname><given-names>T</given-names></name><name><surname>Aktas</surname><given-names>G</given-names></name><name><surname>Kalender</surname><given-names>ME</given-names></name><name><surname>Demiryurek</surname><given-names>AT</given-names></name><name><surname>Ulasli</surname><given-names>M</given-names></name><name><surname>Oztuzcu</surname><given-names>S</given-names></name><name><surname>Sevinc</surname><given-names>A</given-names></name><name><surname>Kul</surname><given-names>S</given-names></name><name><surname>Camci</surname><given-names>C</given-names></name></person-group><article-title>Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel</article-title><source>Onco Targets Ther</source><year>2016</year><volume>9</volume><fpage>5073</fpage><lpage>5080</lpage><pub-id pub-id-type="doi">10.2147/ott.S106574</pub-id><pub-id pub-id-type="pmid">27574448</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Kus T, Aktas G, Kalender ME, Demiryurek AT, Ulasli M, Oztuzcu S, Sevinc A, Kul S, Camci C (2016) Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. Onco Targets Ther 9:5073&#x02013;5080. 10.2147/ott.S106574<pub-id pub-id-type="pmid">27574448</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Ahern</surname><given-names>TP</given-names></name><name><surname>Collin</surname><given-names>LJ</given-names></name><name><surname>Baurley</surname><given-names>JW</given-names></name><name><surname>Kj&#x000e6;rsgaard</surname><given-names>A</given-names></name><name><surname>Nash</surname><given-names>R</given-names></name><name><surname>Maliniak</surname><given-names>ML</given-names></name><name><surname>Damkier</surname><given-names>P</given-names></name><name><surname>Zwick</surname><given-names>ME</given-names></name><name><surname>Isett</surname><given-names>RB</given-names></name><name><surname>Christiansen</surname><given-names>PM</given-names></name><name><surname>Ejlertsen</surname><given-names>B</given-names></name><name><surname>Lauridsen</surname><given-names>KL</given-names></name><name><surname>Christensen</surname><given-names>KB</given-names></name><name><surname>Silliman</surname><given-names>RA</given-names></name><name><surname>S&#x000f8;rensen</surname><given-names>HT</given-names></name><name><surname>Tramm</surname><given-names>T</given-names></name><name><surname>Hamilton-Dutoit</surname><given-names>S</given-names></name><name><surname>Lash</surname><given-names>TL</given-names></name><name><surname>Cronin-Fenton</surname><given-names>D</given-names></name></person-group><article-title>Metabolic pathway analysis and effectiveness of tamoxifen in danish breast cancer patients</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2020</year><volume>29</volume><fpage>582</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.Epi-19-0833</pub-id><pub-id pub-id-type="pmid">31932415</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Ahern TP, Collin LJ, Baurley JW, Kj&#x000e6;rsgaard A, Nash R, Maliniak ML, Damkier P, Zwick ME, Isett RB, Christiansen PM, Ejlertsen B, Lauridsen KL, Christensen KB, Silliman RA, S&#x000f8;rensen HT, Tramm T, Hamilton-Dutoit S, Lash TL, Cronin-Fenton D (2020) Metabolic pathway analysis and effectiveness of tamoxifen in danish breast cancer patients. Cancer Epidemiol Biomarkers Prev 29:582&#x02013;590. 10.1158/1055-9965.Epi-19-0833<pub-id pub-id-type="pmid">31932415</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Hjorth</surname><given-names>CF</given-names></name><name><surname>Damkier</surname><given-names>P</given-names></name><name><surname>Stage</surname><given-names>TB</given-names></name><name><surname>Feddersen</surname><given-names>S</given-names></name><name><surname>Hamilton-Dutoit</surname><given-names>S</given-names></name><name><surname>Ejlertsen</surname><given-names>B</given-names></name><name><surname>Lash</surname><given-names>TL</given-names></name><name><surname>B&#x000f8;ggild</surname><given-names>H</given-names></name><name><surname>S&#x000f8;rensen</surname><given-names>HT</given-names></name><name><surname>Cronin-Fenton</surname><given-names>D</given-names></name></person-group><article-title>The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer</article-title><source>Cancer Chemother Pharmacol</source><year>2023</year><volume>91</volume><fpage>157</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1007/s00280-022-04499-z</pub-id><pub-id pub-id-type="pmid">36598552</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Hjorth CF, Damkier P, Stage TB, Feddersen S, Hamilton-Dutoit S, Ejlertsen B, Lash TL, B&#x000f8;ggild H, S&#x000f8;rensen HT, Cronin-Fenton D (2023) The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer. Cancer Chemother Pharmacol 91:157&#x02013;165. 10.1007/s00280-022-04499-z<pub-id pub-id-type="pmid">36598552</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>SAJ</given-names></name><name><surname>Adelborg</surname><given-names>K</given-names></name><name><surname>Sundb&#x000f8;ll</surname><given-names>J</given-names></name><name><surname>Laugesen</surname><given-names>K</given-names></name><name><surname>Ehrenstein</surname><given-names>V</given-names></name><name><surname>S&#x000f8;rensen</surname><given-names>HT</given-names></name></person-group><article-title>The Danish health care system and epidemiological research: from health care contacts to database records</article-title><source>Clin Epidemiol</source><year>2019</year><volume>11</volume><fpage>563</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.2147/clep.S179083</pub-id><pub-id pub-id-type="pmid">31372058</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Schmidt M, Schmidt SAJ, Adelborg K, Sundb&#x000f8;ll J, Laugesen K, Ehrenstein V, S&#x000f8;rensen HT (2019) The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol 11:563&#x02013;591. 10.2147/clep.S179083<pub-id pub-id-type="pmid">31372058</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Christiansen</surname><given-names>P</given-names></name><name><surname>Ejlertsen</surname><given-names>B</given-names></name><name><surname>Jensen</surname><given-names>MB</given-names></name><name><surname>Mouridsen</surname><given-names>H</given-names></name></person-group><article-title>Danish breast cancer cooperative group</article-title><source>Clin Epidemiol</source><year>2016</year><volume>8</volume><fpage>445</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.2147/clep.S99457</pub-id><pub-id pub-id-type="pmid">27822082</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Christiansen P, Ejlertsen B, Jensen MB, Mouridsen H (2016) Danish breast cancer cooperative group. Clin Epidemiol 8:445&#x02013;449. 10.2147/clep.S99457<pub-id pub-id-type="pmid">27822082</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Blichert-Toft</surname><given-names>M</given-names></name><name><surname>Christiansen</surname><given-names>P</given-names></name><name><surname>Mouridsen</surname><given-names>HT</given-names></name></person-group><article-title>Danish breast cancer cooperative group&#x02013;DBCG: history, organization, and status of scientific achievements at 30-year anniversary</article-title><source>Acta Oncol</source><year>2008</year><volume>47</volume><fpage>497</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1080/02841860802068615</pub-id><pub-id pub-id-type="pmid">18465316</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Blichert-Toft M, Christiansen P, Mouridsen HT (2008) Danish breast cancer cooperative group&#x02013;DBCG: history, organization, and status of scientific achievements at 30-year anniversary. Acta Oncol 47:497&#x02013;505. 10.1080/02841860802068615<pub-id pub-id-type="pmid">18465316</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Erichsen</surname><given-names>R</given-names></name><name><surname>Lash</surname><given-names>TL</given-names></name><name><surname>Hamilton-Dutoit</surname><given-names>SJ</given-names></name><name><surname>Bjerregaard</surname><given-names>B</given-names></name><name><surname>Vyberg</surname><given-names>M</given-names></name><name><surname>Pedersen</surname><given-names>L</given-names></name></person-group><article-title>Existing data sources for clinical epidemiology: the Danish national pathology registry and data bank</article-title><source>Clin Epidemiol</source><year>2010</year><volume>2</volume><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.2147/clep.s9908</pub-id><pub-id pub-id-type="pmid">20865103</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Erichsen R, Lash TL, Hamilton-Dutoit SJ, Bjerregaard B, Vyberg M, Pedersen L (2010) Existing data sources for clinical epidemiology: the Danish national pathology registry and data bank. Clin Epidemiol 2:51&#x02013;56. 10.2147/clep.s9908<pub-id pub-id-type="pmid">20865103</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Hjollund</surname><given-names>NH</given-names></name><name><surname>Larsen</surname><given-names>FB</given-names></name><name><surname>Andersen</surname><given-names>JH</given-names></name></person-group><article-title>Register-based follow-up of social benefits and other transfer payments: accuracy and degree of completeness in a Danish interdepartmental administrative database compared with a population-based survey</article-title><source>Scand J Public Health</source><year>2007</year><volume>35</volume><fpage>497</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1080/14034940701271882</pub-id><pub-id pub-id-type="pmid">17852980</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Hjollund NH, Larsen FB, Andersen JH (2007) Register-based follow-up of social benefits and other transfer payments: accuracy and degree of completeness in a Danish interdepartmental administrative database compared with a population-based survey. Scand J Public Health 35:497&#x02013;502. 10.1080/14034940701271882<pub-id pub-id-type="pmid">17852980</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Stapelfeldt</surname><given-names>CM</given-names></name><name><surname>Jensen</surname><given-names>C</given-names></name><name><surname>Andersen</surname><given-names>NT</given-names></name><name><surname>Fleten</surname><given-names>N</given-names></name><name><surname>Nielsen</surname><given-names>CV</given-names></name></person-group><article-title>Validation of sick leave measures: self-reported sick leave and sickness benefit data from a Danish national register compared to multiple workplace-registered sick leave spells in a Danish municipality</article-title><source>BMC Public Health</source><year>2012</year><volume>12</volume><fpage>661</fpage><pub-id pub-id-type="doi">10.1186/1471-2458-12-661</pub-id><pub-id pub-id-type="pmid">22894644</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Stapelfeldt CM, Jensen C, Andersen NT, Fleten N, Nielsen CV (2012) Validation of sick leave measures: self-reported sick leave and sickness benefit data from a Danish national register compared to multiple workplace-registered sick leave spells in a Danish municipality. BMC Public Health 12:661. 10.1186/1471-2458-12-661<pub-id pub-id-type="pmid">22894644</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>SA</given-names></name><name><surname>Sandegaard</surname><given-names>JL</given-names></name><name><surname>Ehrenstein</surname><given-names>V</given-names></name><name><surname>Pedersen</surname><given-names>L</given-names></name><name><surname>S&#x000f8;rensen</surname><given-names>HT</given-names></name></person-group><article-title>The Danish national patient registry: a review of content, data quality, and research potential</article-title><source>Clin Epidemiol</source><year>2015</year><volume>7</volume><fpage>449</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.2147/clep.S91125</pub-id><pub-id pub-id-type="pmid">26604824</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, S&#x000f8;rensen HT (2015) The Danish national patient registry: a review of content, data quality, and research potential. Clin Epidemiol 7:449&#x02013;490. 10.2147/clep.S91125<pub-id pub-id-type="pmid">26604824</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Statistics Denmark (2023) Husstande og familier [Housholds and families]. <ext-link ext-link-type="uri" xlink:href="https://www.dst.dk/da/Statistik/emner/borgere/husstande-familier-og-boern/husstande-og-familier">https://www.dst.dk/da/Statistik/emner/borgere/husstande-familier-og-boern/husstande-og-familier</ext-link>. Accessed 20 Mar 2023</mixed-citation></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>VM</given-names></name><name><surname>Rasmussen</surname><given-names>AW</given-names></name></person-group><article-title>Danish education registers</article-title><source>Scand J Public Health</source><year>2011</year><volume>39</volume><fpage>91</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1177/1403494810394715</pub-id><pub-id pub-id-type="pmid">21775362</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Jensen VM, Rasmussen AW (2011) Danish education registers. Scand J Public Health 39:91&#x02013;94. 10.1177/1403494810394715<pub-id pub-id-type="pmid">21775362</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Collin</surname><given-names>LJ</given-names></name><name><surname>Cronin-Fenton</surname><given-names>DP</given-names></name><name><surname>Ahern</surname><given-names>TP</given-names></name><name><surname>Christiansen</surname><given-names>PM</given-names></name><name><surname>Damkier</surname><given-names>P</given-names></name><name><surname>Ejlertsen</surname><given-names>B</given-names></name><name><surname>Hamilton-Dutoit</surname><given-names>S</given-names></name><name><surname>Kj&#x000e6;rsgaard</surname><given-names>A</given-names></name><name><surname>Silliman</surname><given-names>RA</given-names></name><name><surname>S&#x000f8;rensen</surname><given-names>HT</given-names></name><name><surname>Lash</surname><given-names>TL</given-names></name></person-group><article-title>Cohort profile: the predictors of breast cancer recurrence (ProBe CaRE) premenopausal breast cancer cohort study in Denmark</article-title><source>BMJ Open</source><year>2018</year><volume>8</volume><fpage>e021805</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2018-021805</pub-id><pub-id pub-id-type="pmid">30068618</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Collin LJ, Cronin-Fenton DP, Ahern TP, Christiansen PM, Damkier P, Ejlertsen B, Hamilton-Dutoit S, Kj&#x000e6;rsgaard A, Silliman RA, S&#x000f8;rensen HT, Lash TL (2018) Cohort profile: the predictors of breast cancer recurrence (ProBe CaRE) premenopausal breast cancer cohort study in Denmark. BMJ Open 8:e021805. 10.1136/bmjopen-2018-021805<pub-id pub-id-type="pmid">30068618</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Cronin-Fenton</surname><given-names>DP</given-names></name><name><surname>Kj&#x000e6;rsgaard</surname><given-names>A</given-names></name><name><surname>Ahern</surname><given-names>TP</given-names></name><name><surname>Mele</surname><given-names>M</given-names></name><name><surname>Ewertz</surname><given-names>M</given-names></name><name><surname>Hamilton-Dutoit</surname><given-names>S</given-names></name><name><surname>Christiansen</surname><given-names>PM</given-names></name><name><surname>Ejlertsen</surname><given-names>B</given-names></name><name><surname>S&#x000f8;rensen</surname><given-names>HT</given-names></name><name><surname>Lash</surname><given-names>TL</given-names></name><name><surname>Silliman</surname><given-names>RA</given-names></name></person-group><article-title>Validity of Danish breast cancer group (DBCG) registry data used in the predictors of breast cancer recurrence (ProBeCaRe) premenopausal breast cancer cohort study</article-title><source>Acta Oncol</source><year>2017</year><volume>56</volume><fpage>1155</fpage><lpage>1160</lpage><pub-id pub-id-type="doi">10.1080/0284186x.2017.1327720</pub-id><pub-id pub-id-type="pmid">28585885</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Cronin-Fenton DP, Kj&#x000e6;rsgaard A, Ahern TP, Mele M, Ewertz M, Hamilton-Dutoit S, Christiansen PM, Ejlertsen B, S&#x000f8;rensen HT, Lash TL, Silliman RA (2017) Validity of Danish breast cancer group (DBCG) registry data used in the predictors of breast cancer recurrence (ProBeCaRe) premenopausal breast cancer cohort study. Acta Oncol 56:1155&#x02013;1160. 10.1080/0284186x.2017.1327720<pub-id pub-id-type="pmid">28585885</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000f8;ller</surname><given-names>S</given-names></name><name><surname>Jensen</surname><given-names>MB</given-names></name><name><surname>Ejlertsen</surname><given-names>B</given-names></name><name><surname>Bjerre</surname><given-names>KD</given-names></name><name><surname>Larsen</surname><given-names>M</given-names></name><name><surname>Hansen</surname><given-names>HB</given-names></name><name><surname>Christiansen</surname><given-names>P</given-names></name><name><surname>Mouridsen</surname><given-names>HT</given-names></name></person-group><article-title>The clinical database and the treatment guidelines of the Danish breast cancer cooperative group (DBCG); its 30-years experience and future promise</article-title><source>Acta Oncol</source><year>2008</year><volume>47</volume><fpage>506</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1080/02841860802059259</pub-id><pub-id pub-id-type="pmid">18465317</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">M&#x000f8;ller S, Jensen MB, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB, Christiansen P, Mouridsen HT (2008) The clinical database and the treatment guidelines of the Danish breast cancer cooperative group (DBCG); its 30-years experience and future promise. Acta Oncol 47:506&#x02013;524. 10.1080/02841860802059259<pub-id pub-id-type="pmid">18465317</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Ejlertsen</surname><given-names>B</given-names></name><name><surname>Tuxen</surname><given-names>MK</given-names></name><name><surname>Jakobsen</surname><given-names>EH</given-names></name><name><surname>Jensen</surname><given-names>MB</given-names></name><name><surname>Knoop</surname><given-names>AS</given-names></name><name><surname>H&#x000f8;jris</surname><given-names>I</given-names></name><name><surname>Ewertz</surname><given-names>M</given-names></name><name><surname>Balslev</surname><given-names>E</given-names></name><name><surname>Dan&#x000f8;</surname><given-names>H</given-names></name><name><surname>Vestlev</surname><given-names>PM</given-names></name><name><surname>Kenholm</surname><given-names>J</given-names></name><name><surname>Nielsen</surname><given-names>DL</given-names></name><name><surname>Bechmann</surname><given-names>T</given-names></name><name><surname>Andersson</surname><given-names>M</given-names></name><name><surname>Cold</surname><given-names>S</given-names></name><name><surname>Nielsen</surname><given-names>HM</given-names></name><name><surname>Maae</surname><given-names>E</given-names></name><name><surname>Carlsen</surname><given-names>D</given-names></name><name><surname>Mouridsen</surname><given-names>HT</given-names></name></person-group><article-title>Adjuvant cyclophosphamide and docetaxel with or without epirubicin for early TOP2A-normal breast cancer: DBCG 07-READ, an open-label, phase III, randomized trial</article-title><source>J Clin Oncol</source><year>2017</year><volume>35</volume><fpage>2639</fpage><lpage>2646</lpage><pub-id pub-id-type="doi">10.1200/jco.2017.72.3494</pub-id><pub-id pub-id-type="pmid">28661759</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Ejlertsen B, Tuxen MK, Jakobsen EH, Jensen MB, Knoop AS, H&#x000f8;jris I, Ewertz M, Balslev E, Dan&#x000f8; H, Vestlev PM, Kenholm J, Nielsen DL, Bechmann T, Andersson M, Cold S, Nielsen HM, Maae E, Carlsen D, Mouridsen HT (2017) Adjuvant cyclophosphamide and docetaxel with or without epirubicin for early TOP2A-normal breast cancer: DBCG 07-READ, an open-label, phase III, randomized trial. J Clin Oncol 35:2639&#x02013;2646. 10.1200/jco.2017.72.3494<pub-id pub-id-type="pmid">28661759</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Hjorth</surname><given-names>CF</given-names></name><name><surname>Damkier</surname><given-names>P</given-names></name><name><surname>Stage</surname><given-names>TB</given-names></name><name><surname>Feddersen</surname><given-names>S</given-names></name><name><surname>Hamilton-Dutoit</surname><given-names>S</given-names></name><name><surname>R&#x000f8;rth</surname><given-names>M</given-names></name><name><surname>Ejlertsen</surname><given-names>B</given-names></name><name><surname>Lash</surname><given-names>TL</given-names></name><name><surname>Ahern</surname><given-names>TP</given-names></name><name><surname>S&#x000f8;rensen</surname><given-names>HT</given-names></name><name><surname>Cronin-Fenton</surname><given-names>D</given-names></name></person-group><article-title>Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark</article-title><source>Breast Cancer Res Treat</source><year>2022</year><volume>194</volume><fpage>353</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1007/s10549-022-06596-2</pub-id><pub-id pub-id-type="pmid">35501422</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Hjorth CF, Damkier P, Stage TB, Feddersen S, Hamilton-Dutoit S, R&#x000f8;rth M, Ejlertsen B, Lash TL, Ahern TP, S&#x000f8;rensen HT, Cronin-Fenton D (2022) Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark. Breast Cancer Res Treat 194:353&#x02013;363. 10.1007/s10549-022-06596-2<pub-id pub-id-type="pmid">35501422</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Hjorth</surname><given-names>CF</given-names></name><name><surname>Schmidt</surname><given-names>JA</given-names></name><name><surname>Farkas</surname><given-names>DK</given-names></name><name><surname>Cronin-Fenton</surname><given-names>D</given-names></name></person-group><article-title>Social characteristics and social benefit use among premenopausal breast cancer survivors in Denmark: a population-based cohort study</article-title><source>J Cancer Surviv</source><year>2024</year><pub-id pub-id-type="doi">10.1007/s11764-024-01598-z</pub-id><pub-id pub-id-type="pmid">38647591</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Hjorth CF, Schmidt JA, Farkas DK, Cronin-Fenton D (2024) Social characteristics and social benefit use among premenopausal breast cancer survivors in Denmark: a population-based cohort study. J Cancer Surviv. 10.1007/s11764-024-01598-z<pub-id pub-id-type="pmid">38647591</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">DA Analysis (2019) Store omkostninger ved sygefrav&#x000e6;r g&#x000f8;r det sv&#x000e6;rt for virksomhederne at integrere folk p&#x000e5; kanten af arbejdsmarkedet [Extensive costs of sick leave make it difficult for companies to integrate people on the edge of the labour market]. <ext-link ext-link-type="uri" xlink:href="https://www.da.dk/politik-og-analyser/beskaeftigelse/2019/store-omkostninger-ved-sygefravaer-goer-det-svaert-for-virksomhederne-at-integrere-folk-paa-kanten-af-arbejdsmarkedet/">https://www.da.dk/politik-og-analyser/beskaeftigelse/2019/store-omkostninger-ved-sygefravaer-goer-det-svaert-for-virksomhederne-at-integrere-folk-paa-kanten-af-arbejdsmarkedet/</ext-link>. Accessed 6 Mar 2024</mixed-citation></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>V</given-names></name><name><surname>Lundager</surname><given-names>B</given-names></name><name><surname>Christensen</surname><given-names>AL</given-names></name><name><surname>Fonager</surname><given-names>K</given-names></name></person-group><article-title>Unemployment under the flex job scheme increases the risk of permanent social security benefits</article-title><source>Dan Med J</source><year>2014</year><volume>61</volume><fpage>A4804</fpage><pub-id pub-id-type="pmid">24814586</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Jensen V, Lundager B, Christensen AL, Fonager K (2014) Unemployment under the flex job scheme increases the risk of permanent social security benefits. Dan Med J 61:A4804<pub-id pub-id-type="pmid">24814586</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Charlson</surname><given-names>ME</given-names></name><name><surname>Pompei</surname><given-names>P</given-names></name><name><surname>Ales</surname><given-names>KL</given-names></name><name><surname>MacKenzie</surname><given-names>CR</given-names></name></person-group><article-title>A new method of classifying prognostic comorbidity in longitudinal studies: development and validation</article-title><source>J Chronic Dis</source><year>1987</year><volume>40</volume><fpage>373</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1016/0021-9681(87)90171-8</pub-id><pub-id pub-id-type="pmid">3558716</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373&#x02013;383. 10.1016/0021-9681(87)90171-8<pub-id pub-id-type="pmid">3558716</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Kvillemo</surname><given-names>P</given-names></name><name><surname>Mittendorfer-Rutz</surname><given-names>E</given-names></name><name><surname>Br&#x000e4;nstr&#x000f6;m</surname><given-names>R</given-names></name><name><surname>Nilsson</surname><given-names>K</given-names></name><name><surname>Alexanderson</surname><given-names>K</given-names></name></person-group><article-title>Sickness absence and disability pension after breast cancer diagnosis: a 5-Year nationwide cohort study</article-title><source>J Clin Oncol</source><year>2017</year><volume>35</volume><fpage>2044</fpage><lpage>2052</lpage><pub-id pub-id-type="doi">10.1200/jco.2015.66.0613</pub-id><pub-id pub-id-type="pmid">28459607</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Kvillemo P, Mittendorfer-Rutz E, Br&#x000e4;nstr&#x000f6;m R, Nilsson K, Alexanderson K (2017) Sickness absence and disability pension after breast cancer diagnosis: a 5-Year nationwide cohort study. J Clin Oncol 35:2044&#x02013;2052. 10.1200/jco.2015.66.0613<pub-id pub-id-type="pmid">28459607</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Staff</surname><given-names>NP</given-names></name><name><surname>Fehrenbacher</surname><given-names>JC</given-names></name><name><surname>Caillaud</surname><given-names>M</given-names></name><name><surname>Damaj</surname><given-names>MI</given-names></name><name><surname>Segal</surname><given-names>RA</given-names></name><name><surname>Rieger</surname><given-names>S</given-names></name></person-group><article-title>Pathogenesis of paclitaxel-induced peripheral neuropathy: a current review of in vitro and in vivo findings using rodent and human model systems</article-title><source>Exp Neurol</source><year>2020</year><volume>324</volume><fpage>113121</fpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2019.113121</pub-id><pub-id pub-id-type="pmid">31758983</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Staff NP, Fehrenbacher JC, Caillaud M, Damaj MI, Segal RA, Rieger S (2020) Pathogenesis of paclitaxel-induced peripheral neuropathy: a current review of in vitro and in vivo findings using rodent and human model systems. Exp Neurol 324:113121. 10.1016/j.expneurol.2019.113121<pub-id pub-id-type="pmid">31758983</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Argyriou</surname><given-names>AA</given-names></name><name><surname>Bruna</surname><given-names>J</given-names></name><name><surname>Genazzani</surname><given-names>AA</given-names></name><name><surname>Cavaletti</surname><given-names>G</given-names></name></person-group><article-title>Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics</article-title><source>Nat Rev Neurol</source><year>2017</year><volume>13</volume><fpage>492</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2017.88</pub-id><pub-id pub-id-type="pmid">28664909</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Argyriou AA, Bruna J, Genazzani AA, Cavaletti G (2017) Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics. Nat Rev Neurol 13:492&#x02013;504. 10.1038/nrneurol.2017.88<pub-id pub-id-type="pmid">28664909</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Lash</surname><given-names>TL</given-names></name><name><surname>Cole</surname><given-names>SR</given-names></name></person-group><article-title>Immortal person-time in studies of cancer outcomes</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>e55</fpage><lpage>e56</lpage><pub-id pub-id-type="doi">10.1200/jco.2009.24.1877</pub-id><pub-id pub-id-type="pmid">19597013</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Lash TL, Cole SR (2009) Immortal person-time in studies of cancer outcomes. J Clin Oncol 27:e55&#x02013;e56. 10.1200/jco.2009.24.1877<pub-id pub-id-type="pmid">19597013</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Ahern</surname><given-names>TP</given-names></name><name><surname>Christensen</surname><given-names>M</given-names></name><name><surname>Cronin-Fenton</surname><given-names>DP</given-names></name><name><surname>Lunetta</surname><given-names>KL</given-names></name><name><surname>Rosenberg</surname><given-names>CL</given-names></name><name><surname>S&#x000f8;rensen</surname><given-names>HT</given-names></name><name><surname>Lash</surname><given-names>TL</given-names></name><name><surname>Hamilton-Dutoit</surname><given-names>S</given-names></name></person-group><article-title>Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue</article-title><source>Clin Epidemiol</source><year>2010</year><volume>2</volume><fpage>241</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.2147/clep.S13811</pub-id><pub-id pub-id-type="pmid">21152250</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Ahern TP, Christensen M, Cronin-Fenton DP, Lunetta KL, Rosenberg CL, S&#x000f8;rensen HT, Lash TL, Hamilton-Dutoit S (2010) Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue. Clin Epidemiol 2:241&#x02013;246. 10.2147/clep.S13811<pub-id pub-id-type="pmid">21152250</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Hertz</surname><given-names>DL</given-names></name><name><surname>Kidwell</surname><given-names>KM</given-names></name><name><surname>Thibert</surname><given-names>JN</given-names></name><name><surname>Gersch</surname><given-names>C</given-names></name><name><surname>Regan</surname><given-names>MM</given-names></name><name><surname>Skaar</surname><given-names>TC</given-names></name><name><surname>Henry</surname><given-names>NL</given-names></name><name><surname>Hayes</surname><given-names>DF</given-names></name><name><surname>Van Poznak</surname><given-names>CH</given-names></name><name><surname>Rae</surname><given-names>JM</given-names></name></person-group><article-title>Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses</article-title><source>Mol Oncol</source><year>2015</year><volume>9</volume><fpage>1868</fpage><lpage>1876</lpage><pub-id pub-id-type="doi">10.1016/j.molonc.2015.07.002</pub-id><pub-id pub-id-type="pmid">26276228</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Hertz DL, Kidwell KM, Thibert JN, Gersch C, Regan MM, Skaar TC, Henry NL, Hayes DF, Van Poznak CH, Rae JM (2015) Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses. Mol Oncol 9:1868&#x02013;1876. 10.1016/j.molonc.2015.07.002<pub-id pub-id-type="pmid">26276228</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>